GLP-1 drugs have become one of the most important developments in the pharmaceutical industry. With products like Ozempic, Wegovy, and Mounjaro in high demand, competition between drug makers is growing quickly.

In this episode of Down to Business English, Skip Montreux and Dez Morgan get Down to Business with GLP-1 inhibitors — the drugs behind today’s weight-loss boom. They explain who the main players are, including Novo Nordisk and Eli Lilly, and compare their leading products. Their discussion also looks at a major recent development: Pfizer’s acquisition of biopharma startup Metsera, and why this deal could significantly change the market.

Skip and Dez’s conversation gives listeners a clear and practical introduction to competition and strategy in the pharmaceutical industry — while helping you improve your Business English. In this episode, you will learn:

What GLP-1 drugs are and what they are used for.
The main differences between Ozempic, Wegovy, Mounjaro, and Zepbound.
Why Eli Lilly is gaining market share, especially in North America.
How Pfizer’s acquisition could affect future weight-loss treatments.

Do you like what you hear?

Become a D2B Member today for to access to our -- NEW!!!-- interactive audio scripts, PDF Audio Script Library, Bonus Vocabulary episodes, and D2B Member-only episodes.

Visit d2benglish.com/membership for more information.

Follow Down to Business English on Apple podcasts, rate the show, and leave a comment.

Contact Skip, Dez, and Samantha at

downtobusinessenglish@gmail.com

Follow Skip & Dez

Skip Montreux on Linkedin

Skip Montreux on Instagram

Skip Montreux on Twitter

Skip Montreux on Facebook

Dez Morgan on Twitter

RSS Feed

GLP-1 Inhibitors

Down to Business English